-- Funding to support clinical development of multiple antibody-drug conjugate (ADC) programs -- Utilizing the Synaffix platform designed to minimize off-target toxicity and improve efficacy -- ...
It doesn’t matter how well a drug kills cancer cells if the patient doesn’t stay on treatment. Side effects lead many patients to interrupt dosing of a drug regimen, allowing cancer to advance, said ...
KIVU-107 is the first PTK7-targeting ADC with a DAR4 exatecan payload, engineered for exceptional stability and highly selective on-tumor delivery. Preclinical data demonstrate deeper and durable anti ...
Fighting between the M23 armed group and the Congolese armed forces and their respective allies has exacerbated already severe humanitarian needs and compromised the delivery of aid. Action Against ...
SAN FRANCISCO--(BUSINESS WIRE)--Kivu Bioscience, a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class therapeutics, announced today the close of a $92 million ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback